TY - JOUR
T1 - Radiofrequency ablation vs. Cryoablation for localized hepatocellular carcinoma
T2 - A propensity-matched population study
AU - Xu, Jimmy
AU - Noda, Christopher
AU - Erickson, Abigail
AU - Mokkarala, Mahati
AU - Charalel, Resmi
AU - Ramaswamy, Raja
AU - Tao, Yu
AU - Akinwande, Olaguoke
N1 - Funding Information:
This study was exempt from institutional review board approval and was completed in accordance with the National Cancer Institute SEER user agreement. The SEER database collects cancer statistics pooled from 18 registries, covering approximately 28% of the American population, from diverse geographic locations throughout the country. Collected data includes patient demographics, primary tumor site, tumor morphology, stage at diagnosis, first course of treatment, and survival. Data collection was standardized to ensure that individual state registry data is acceptable for subsequent data pooling (1).
Publisher Copyright:
© 2018 International Institute of Anticancer Research.All right reserved.
PY - 2018/11
Y1 - 2018/11
N2 - Background/Aim: To compare overall survival (OS) and liver cancer-specific survival (LCSS) of Surveillance, Epidemiology and End Results (SEER) hepatocellular carcinoma (HCC) database patients treated with cryoablation (cryo) or radiofrequency ablation (RFA). Materials and Methods: This was a retrospective review of Stage I or II HCC patients from the SEER database treated with cryo and RFA from 2004-2013. Kaplan-Meier and Cox regressions were performed on pooled and propensity-matched cohort. Results: Out of 3,239 patients, RFA showed a significant survival advantage over cryo in liver cancer specific survival (LCSS) (HR=1.634 p=0.0004). A total of 91 propensity-matched pairs had similar OS (HR=1.006 p=0.9768), but no difference in LCSS was observed between the groups [HR=1.412 (95%CI=0.933-2.137) p=0.1023]. Survival Cox models did not reveal treatment type as an independent prognostic factor. Conclusion: Propensity-matched cohort showed no significant difference in terms of OS and LCSS was found for patients treated with either cryo or RFA for localized HCC.
AB - Background/Aim: To compare overall survival (OS) and liver cancer-specific survival (LCSS) of Surveillance, Epidemiology and End Results (SEER) hepatocellular carcinoma (HCC) database patients treated with cryoablation (cryo) or radiofrequency ablation (RFA). Materials and Methods: This was a retrospective review of Stage I or II HCC patients from the SEER database treated with cryo and RFA from 2004-2013. Kaplan-Meier and Cox regressions were performed on pooled and propensity-matched cohort. Results: Out of 3,239 patients, RFA showed a significant survival advantage over cryo in liver cancer specific survival (LCSS) (HR=1.634 p=0.0004). A total of 91 propensity-matched pairs had similar OS (HR=1.006 p=0.9768), but no difference in LCSS was observed between the groups [HR=1.412 (95%CI=0.933-2.137) p=0.1023]. Survival Cox models did not reveal treatment type as an independent prognostic factor. Conclusion: Propensity-matched cohort showed no significant difference in terms of OS and LCSS was found for patients treated with either cryo or RFA for localized HCC.
KW - Cryoablation
KW - Hepatocellular carcinoma
KW - Liver cancer specific survival
KW - Propensity matching
KW - Radiofrequency ablation
KW - Surveillance epide-miology and end results database
UR - http://www.scopus.com/inward/record.url?scp=85056094216&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12997
DO - 10.21873/anticanres.12997
M3 - Article
C2 - 30396961
AN - SCOPUS:85056094216
VL - 38
SP - 6381
EP - 6386
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 11
ER -